Reply letter to: Inhibition of SARS-CoV-2 replication using calcineurin inhibitors: Are concentrations required clinically achievable?

Gálvez-Romero, J L; Deveaux-Homs, J; Real-Ramírez, F A; Palmeros-Rojas, O; Pedraza-Sánchez, S

Gálvez-Romero, J L; Deveaux-Homs, J; Real-Ramírez, F A; Palmeros-Rojas, O; Pedraza-Sánchez, S.

Gálvez-Romero JL; From the, Departamento de Investigación, Hospital Regional Puebla del ISSSTE, Puebla, México.
Deveaux-Homs J; Dirección Médica, Hospital Regional Puebla del ISSSTE, Puebla, México.
Real-Ramírez FA; Departamento de Medicina Interna, Hospital Regional Puebla del ISSSTE, Puebla, México.
Palmeros-Rojas O; Área de Matemáticas, Universidad Autónoma de Chapingo, Texcoco, México.
Pedraza-Sánchez S; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), Tlalpan, México.

J Intern Med ; 289(6): 928-929, 2021 06.

Article in English | MEDLINE | ID: covidwho-1388330

Subject(s)

COVID-19; SARS-CoV-2; Antiviral Agents; Calcineurin Inhibitors/pharmacology; Humans; Virus Replication

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Prognostic study Limits: Humans Language: English Journal: J Intern Med Journal subject: Internal Medicine Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google